Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
By W.T.A. van der Graaf, J. Blay, S. Chawla, Dong-Wan Kim, B. Bui-Nguyen, P. Casali, P. Schöffski, M. Aglietta, A. Staddon, Y. Beppu and 13 more. The Lancet, 2012
1,896 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/44ce5d7e247796253ce223cf0da8b180168a0bcd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “• A randomised trial showed a benefit in PFS averaging 3 months for pazopanib given up to progression to advanced, previously treated, STS patients (excluding liposarcomas) [31].”
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, positive): “• A randomised trial showed a benefit in PFS averaging 3 months for pazopanib given until progression to advanced, previously treated STS patients (excluding liposarcomas) [41].”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “40) 3 [136]”